Japan approves GSK's Exdensur for asthma and chronic rhinosinusitis with nasal polyps

Japan has officially sanctioned Exdensur (depemokimab) as a pioneering, ultra-long-lasting biological therapy. This medication is now available for individuals struggling with intense bronchial asthma or chronic rhinosinusitis accompanied by nasal polyps (CRSwNP) who haven't found relief through traditional medical approaches.

What distinguishes Exdensur from existing options?

Developed by GSK, Exdensur biologic targets type 2 inflammation by binding to interleukin-5 (IL-5) with high precision. Its unique chemical structure allows it to remain active in the body much longer than previous generations, requiring only two injections per year. This breakthrough offers a significant reduction in the therapeutic burden for patients who previously relied on more frequent clinical visits.

Also read: Top 10 pharmaceutical companies by revenue 2025

Evidence of Success: The SWIFT and ANCHOR Studies

The Japanese Ministry of Health, Labour and Welfare based its decision on robust clinical evidence gathered from four global Phase III investigations.

Asthma Management (SWIFT-1 and SWIFT-2)

These trials highlighted that depemokimab dramatically lowered the frequency of annual asthma attacks compared to a dummy drug. Specifically, one study showed a 58% decrease in exacerbations, while the second reported a 48% reduction.

Nasal Polyp Relief (ANCHOR-1 and ANCHOR-2):

or those suffering from CRSwNP, the drug effectively shrunk the size of nasal growths and cleared physical blockages in the nasal passages.

Throughout these studies, the medication demonstrated a safety record comparable to the placebo, suggesting it is well-tolerated by the majority of users.

Also read: Novartis hopes its cancer drugs drive revenues until 2030

Addressing Unmet Medical Needs

In Japan, many asthma sufferers face a deteriorating quality of life characterized by emergency room visits and progressive lung damage. Similarly, nearly half of those with CRSwNP continue to experience debilitating symptoms like loss of smell, facial pressure, and sleep disruption despite standard care.

By suppressing the eosinophils and inflammatory signals responsible for these conditions, Exdensur aims to stabilize the health of these patients over long periods, potentially lowering the strain on the broader Japanese healthcare infrastructure.

Global Regulatory Status

This Japanese clearance represents the third major milestone for the drug, following successful authorizations in the United States and the United Kingdom. European health authorities have also issued a favorable recommendation, and the therapy is currently under evaluation by regulators in China and other international markets.

Also read: Enhertu approved in China for HER2‑low or HER2‑ultralow metastatic breast cancer

Understanding the Underlying Science

Both severe asthma and CRSwNP are frequently rooted in type 2 inflammation, an overactive immune response found in over 80% of severe cases. This pathway involves high levels of eosinophils—white blood cells that, when overproduced, cause tissue swelling and damage. Exdensur works by neutralizing IL-5, the primary messenger that drives these cells, providing a steady shield against inflammation for six months at a time.